2022年度输血医学科研新进展*

doi:10.3969/j.issn.1671-2587.2023.03.023

临床输血与检验 ›› 2023, Vol. 25 ›› Issue (3): 415-419.DOI: 10.3969/j.issn.1671-2587.2023.03.023

2022年度输血医学科研新进展^*

贺敏威, 詹林盛

100850 军事医学研究院卫生勤务与血液研究所

收稿日期:2023-03-30 发布日期:2023-07-10
通讯作者: 詹林盛,研究员,博士生导师,主要从事输血医学基础与前沿技术研究,（E-mail）amms91@126.com。
作者简介:贺敏威,助理研究员,博士,主要从事输血医学基础与前沿技术研究,（E-mail）minweihe@pku.edu.cn。
基金资助:
^*本课题受国家自然科学基金面上项目（No.81970166）资助

Research Advances in Blood Transfusion Medicine in the Year of 2022

HE Minwei, ZHAN Linsheng

Institute of Health Service and Transfusion Medicine, Beijing 100850

Received:2023-03-30 Published:2023-07-10

摘要/Abstract

摘要： 随着生物组学、生物工程技术和新型纳米材料技术等前沿技术与输血医学的交叉融合,输血医学的进展内容每一年度都会有一定幅度的更新、补充和完善。本文从血细胞生成和替代、血细胞储存损伤和保存新技术、输血免疫反应发生发展机制和临床输血治疗等方面对2022年度输血医学领域的主要研究进展作简要概述。

关键词: 输血, 科研进展, 综述

Abstract: With the application of cutting-edge technologies such as bioomics, bioengineering and novel nanomaterials, our understanding of blood transfusion medicine is constantly improving year by year. Here, we reviewed representative research in the fields of blood generation/replacement, blood cell storage lesion, transfusion related adverse effect, clinical transfusion therapy and provided an insight into the advances of our knowledge in blood transfusion.

Key words: Blood transfusion, Cutting-edge advances, Review

中图分类号:

R457

贺敏威, 詹林盛. 2022年度输血医学科研新进展^*[J]. 临床输血与检验, 2023, 25(3): 415-419.

HE Minwei, ZHAN Linsheng. Research Advances in Blood Transfusion Medicine in the Year of 2022[J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2023, 25(3): 415-419.

参考文献

[1] AN H H,GAGNE A L,MAGUIRE J A,et al.The use of pluripotent stem cells to generate diagnostic tools for transfusion medicine[J]. Blood,2022,140(15):1723-1734.
[2] BTRU.RESTORE clinical trial[EB/OL].https://www.bristol.ac.uk/btru/work/trial.
[3] QIN J H,ZHANG J,JIANG J N,et al. Direct chemical reprogramming of human cord blood erythroblasts to induced megakaryocytes that produce platelets[J]. Cell Stem Cell,2022,29(8):1229-1245.e7.
[4] XIA L J.Engineered platelets for clinical application:a step closer[J]. Blood,2022,140(22):2314-2315.
[5] SUGIMOTO N,KANDA J Y,NAKAMURA S,et al.iPLAT1:the first-in-human clinical trial of iPSC-derived platelets as a phase 1 autologous transfusion study[J]. Blood,2022,140(22):2398-2402.
[6] AZUMA H,AMANO T,KAMIYAMA N,et al.First-in-human phase 1 trial of hemoglobin vesicles as artificial red blood cells developed for use as a transfusion alternative[J]. Blood Adv,2022,6(21):5711-5715.
[7] SUN K Q,ZHANG Y J,D'ALESSANDRO A,et al. Sphingosine-1-phosphate promotes erythrocyte glycolysis and oxygen release for adaptation to high-altitude hypoxia[J]. Nat Commun,2016,7:12086.
[8] HAY A,NEMKOV T,GAMBONI F,et al.Sphingosine 1-phosphate has a negative effect on RBC storage quality[J]. Blood Adv,2023,7(8):1379-1393.
[9] FAN X M,WANG Y,CAI X H,et al.CPT2 K79 acetylation regulates platelet life span[J]. Blood Adv,2022,6(17):4924-4935.
[10] RABCUKA J,BLONSKI S,MELI A,et al.Metabolic reprogramming under hypoxic storage preserves faster oxygen unloading from stored red blood cells[J]. Blood Adv,2022,6(18):5415-5428.
[11] DE BRUIN S,PETERS A L,WIJNBERGE M,et al.Storage of red blood cells in alkaline PAGGGM improves metabolism but has no effect on recovery after transfusion[J]. Blood Adv,2022,6(13):3899-3910.
[12] PANDEY S,MAHATO M,SRINATH P,et al.Intermittent scavenging of storage lesion from stored red blood cells by electrospun nanofibrous sheets enhances their quality and shelf-life[J]. Nat Commun,2022,13:7394.
[13] APTE G,BÖRKE J,ROTHE H,et al. Modulation of platelet-surface activation:current state and future perspectives[J]. ACS Appl Bio Mater,2020,3(9):5574-5589.
[14] APTE G,HIRTZ M,NGUYEN T H.FluidFM-based fabrication of nanopatterns:promising surfaces for platelet storage application[J]. ACS Appl Mater Interfaces,2022,14(21):24133-24143.
[15] SOLDATENKO A,HOYT L R,XU L,et al.Innate and adaptive immunity to transfused allogeneic RBCs in mice requires MyD88[J]. J Immunol,2022,208(4):991-997.
[16] QIU A N,MILLER A,ZOTTI F D,et al.FcγRIV is required for IgG2c mediated enhancement of RBC alloimmunization[J]. Front Immunol,2022,13:972723.
[17] WEBBER A M,BRADSTREET T R,WANG X L,et al.Antigen-guided depletion of anti-HLA antibody-producing cells by HLA-Fc fusion proteins[J]. Blood,2022,140(16):1803-1815.
[18] CABLE R G,GLYNN S A,KISS J E,et al.Iron deficiency in blood donors:the REDS-II Donor Iron Status Evaluation (RISE) study[J]. Transfusion,2012,52(4):702-711.
[19] Z SZCZEPIORKOWSKI, T HOPKINS. Updated strategies to limit or prevent iron deficiency in blood donors, Association bulletin #17-02[EB/OL].(2017-03-16).https://www.aabb.org/docs/default-source/default-document-library/resources/association-bulletins/ab17-02.pdf?sfvrsn=55d7caaf_4. 2017.
[20] HOD E A,BRITTENHAM G M,BITAN Z C,et al.A randomized trial of blood donor iron repletion on red cell quality for transfusion and donor cognition and well-being[J]. Blood,2022,140(25):2730-2739.
[21] BRUUN-RASMUSSEN P,KRAGH ANDERSEN P,BANASIK K,et al.Intervening on the storage time of RBC units and its effects on adverse recipient outcomes using real-world data[J]. Blood,2022,139(25):3647-3654.
[22] SAITO-BENZ M,BENNINGTON K,GRAY C L,et al.Effects of freshly irradiated vs irradiated and stored red blood cell transfusion on cerebral oxygenation in preterm infants[J]. JAMA Pediatr,2022,176(5):e220152.
[23] WHYTE R K.Neurodevelopmental outcome of extremely low-birth-weight infants randomly assigned to restrictive or liberal hemoglobin thresholds for blood transfusion[J]. Semin Perinatol,2012,36(4):290-293.
[24] FRANZ A R,ENGEL C,BASSLER D,et al.Effects of liberal vs restrictive transfusion thresholds on survival and neurocognitive outcomes in extremely low-birth-weight infants[J]. JAMA,2020,324(6):560.
[25] PATEL R M,LUKEMIRE J,SHENVI N,et al.Association of blood donor sex and age with outcomes in very low-birth-weight infants receiving blood transfusion[J]. JAMA Netw Open,2021,4(9):e2123942.
[26] ALSHALANI A,UHEL F,CREMER O L,et al.Donor-recipient sex is associated with transfusion-related outcomes in critically ill patients[J]. Blood Adv,2022,6(11):3260-3267.

2022年度输血医学科研新进展^*

Research Advances in Blood Transfusion Medicine in the Year of 2022

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

关于本刊

作者中心

在线期刊

访问统计

联系我们

[1]	赵立哲, 李剑平, 李晓丰. 肠道菌群与人类ABO血型^*[J]. 临床输血与检验, 2023, 25(3): 297-301.
[2]	陈怡静, 卓海龙, 张怡, 程晨, 骆群. X射线辐照对淋巴细胞的灭活能力及对悬浮红细胞质量的影响研究[J]. 临床输血与检验, 2023, 25(3): 320-323.
[3]	高宗帅, 张海方, 李志强. 同种异体血液输注对创伤性失血患者血浆外泌体miRNA表达的影响^*[J]. 临床输血与检验, 2023, 25(3): 334-341.
[4]	黎欢, 谢佳, 何洪伟, 彭涛, 张利, 谭强, 胡燕, 吴玲. 心脏外科围术期大量输血患者输血相关呼吸系统不良反应回顾性调查[J]. 临床输血与检验, 2023, 25(3): 358-362.
[5]	李正峰, 王佳, 陈萍, 甘珊, 李好, 段灵, 陈鑫, 杨柳春, 王阳, 胡红兵. 儿科住院拟输血患者意外抗体阳性结果分布及影响因素横断面研究[J]. 临床输血与检验, 2023, 25(3): 374-378.
[6]	施艺璇, 何苏英, 彭永正. 电子匹配信息系统辅助的Rh血型五抗原配合性输注的安全性和有效性研究[J]. 临床输血与检验, 2023, 25(3): 379-383.
[7]	中国输血协会免疫血液学专业委员会. 输血依赖型地中海贫血（TDT）患者临床输血中国专家共识[J]. 临床输血与检验, 2023, 25(2): 163-169.
[8]	黄蓉, 张宁洁, 郝珂, 郭天虹, 黄雪原, 谷兰, 傅云峰, 黄远帅, 王勇军, 陈秉宇, 周岚, 桂嵘. 从《AABB技术手册》（18版-20版）看国际输血技术新走向^*[J]. 临床输血与检验, 2023, 25(2): 170-179.
[9]	邓桂花, 龙馨妍, 孙亚纯, 王雷萍, 张传国, 孟庆宝. 智慧型输血医学科的建设[J]. 临床输血与检验, 2023, 25(2): 185-189.
[10]	樊凤艳, 马越云. RhD血型不匹配异基因造血干细胞移植输血RhD血型选择[J]. 临床输血与检验, 2023, 25(2): 189-192.
[11]	王瑞含, 彭娟, 刘浩, 刘久波. 回收式自体输血对高危剖宫产妇凝血功能及血液中胎儿成分的影响^*[J]. 临床输血与检验, 2023, 25(2): 215-219.
[12]	葛霜, 汪德清. 2021—2022年度输血医学研究进展^*[J]. 临床输血与检验, 2023, 25(2): 276-281.
[13]	谢东甫, 黄霞, 杨俊鸿, 孙洁, 张晰, 何涛. 国内外血液安全监测报告若干数据指标的比较与分析^*[J]. 临床输血与检验, 2023, 25(1): 16-20.
[14]	王胜蓝, 贵明飞, 华敏玉, 李鹏, 卓创近, 刘钟梅, 杨霞, 黄霞, 何涛. 急性输血不良反应发生时间调查及分析^*[J]. 临床输血与检验, 2023, 25(1): 33-37.
[15]	周姗姗, 荆亚楠, 侯晓燕, 薛亚飞, 张媛媛, 黄霞, 王敏. 某三甲医院2021~2022年276例输血不良反应回顾性分析^*[J]. 临床输血与检验, 2023, 25(1): 38-43.